India is a major global player in biosimilars, primarily in oncology, diabetes, and supportive care, leveraging its strong manufacturing capabilities, cost advantages, and regulatory alignments with bodies like the US FDA, EMA, and others.

Leading Biosimilars and Details

  1. Trastuzumab (Reference: Herceptin – HER2+ breast cancer and other indications)
    • Key Brands: Ogivri (global/US/EU), CANMAb (India-focused).
    • Manufacturer: Biocon Biologics (often partnered with Viatris/Mylan for global markets).
    • Dosage: Loading dose 4–8 mg/kg IV, maintenance 2–6 mg/kg weekly or every 3 weeks.
    • Pack Size: 150 mg single-dose vial; 420 mg multi-dose vial (lyophilized powder for reconstitution).
    • Export Notes: One of the first Indian biosimilars approved in the US (Ogivri); strong oncology export performer.
  2. Pegfilgrastim (Reference: Neulasta – supportive care for chemotherapy-induced neutropenia)
    • Key Brands: Fulphila (global/US), Pelgraz (EU/others).
    • Manufacturer: Biocon Biologics (Fulphila); Intas Pharmaceuticals / Accord (Pelgraz).
    • Dosage: Single subcutaneous injection of 6 mg per chemotherapy cycle (administered ~24 hours after chemo).
    • Pack Size: 6 mg / 0.6 mL single-dose prefilled syringe.
    • Export Notes: Fulphila gained notable US market share; Intas was an early EU launcher.
  3. Bevacizumab (Reference: Avastin – various cancers including colorectal, lung, etc.)
    • Key Brands: Versavo (Dr. Reddy’s); others from Biocon (e.g., Abevmy/Krabeva).
    • Manufacturer: Dr. Reddy’s Laboratories (Versavo); Biocon Biologics.
    • Dosage: Typically 5–15 mg/kg IV every 2–3 weeks, depending on indication and combination therapy.
    • Pack Size: 100 mg / 4 mL and 400 mg / 16 mL single-use vials.
    • Export Notes: Launched in multiple markets including UK/EU; oncology-focused exports.
  4. Insulin Glargine (Reference: Lantus – diabetes management)
    • Key Brands: Basalog, Semglee.
    • Manufacturer: Biocon Biologics.
    • Dosage: Once-daily subcutaneous injection; individualized based on blood glucose (typically 0.2–0.4 units/kg/day initially).
    • Pack Size: Varies (e.g., 3 mL cartridges/pens or vials; common 100 units/mL strength).
    • Export Notes: Early global success, including Japan and US approvals.
  5. Rituximab (Reference: MabThera/Rituxan – lymphoma, rheumatoid arthritis)
    • Key Brands: Reditux (Dr. Reddy’s) and others.
    • Manufacturer: Dr. Reddy’s Laboratories and other Indian players.
    • Dosage: Typically 375 mg/m² IV infusion weekly or per cycle for oncology; varies for autoimmune.
    • Pack Size: Common 100 mg / 10 mL and 500 mg / 50 mL vials.
    • Export Notes: Pioneer biosimilar with broad international reach.

Additional Context

  • Other Notable Products: Filgrastim (e.g., Intas Accofil – 300 mcg or 480 mcg prefilled syringes), Adalimumab, Infliximab, etc. Details follow similar patterns (vials/syringes for injectable administration).
  • General Trends: Most are injectable (IV or SC). Pack sizes prioritize single-use or multi-dose vials/syringes for hospital/clinic use. Indian manufacturers emphasize WHO-GMP, EU-GMP, and US FDA-compliant facilities for exports.
  • Data Sources: Product-specific info drawn from FDA labels, EMA summaries, company announcements, and Indian market references. Actual availability and pricing vary by country due to regulatory and distribution differences.
Print Friendly, PDF & Email